BHRT vs traditional HRT: which should I ask for and where?

Short answer

• Start by asking a clinician experienced in menopause care (OB/GYN, endocrinologist, or a North American Menopause Society–certified menopause practitioner) for an individualized plan.
• Favor FDA‑approved (traditional) HRT first because it has the best evidence on benefits, risks and consistent dosing. Consider compounded “bioidentical” HRT (BHRT) only if you have a clear, specific reason it’s needed and after discussing the trade‑offs.

What “bioidentical” means — and why it’s confusing

• “Bioidentical” technically means the hormone molecule is chemically identical to human hormones (for example, micronized progesterone and estradiol are bioidentical). Several FDA‑approved products are bioidentical.
• BHRT in common use usually refers to compounded custom products (creams, troches, pellets) made by compounding pharmacies. Those are not FDA‑approved, don’t undergo the same large trials, and can vary in potency and purity.

Evidence, safety and regulation — practical differences

• Traditional (FDA‑approved) HRT: products such as estradiol patches (Vivelle‑Dot, Climara), oral estradiol (Estrace), conjugated estrogens (Premarin), and micronized progesterone (Prometrium) have clinical trials, known dosing, standardized manufacturing, and clearer safety data. Insurance coverage is often available.
• Compounded BHRT: appeals for “custom doses” or nonstandard routes (creams, pellets), but lacks robust safety/efficacy studies. Labs used to guide dosing (like saliva tests) are unreliable. There is risk of inconsistent dosing, contamination, and higher out‑of‑pocket cost. Professional societies (NAMS, ACOG, Endocrine Society) advise caution about compounded BHRT.

Common BHRT approaches to be cautious about

• Pellets (subcutaneous pellets, often marketed by networks such as BioTE): convenience, but limited high‑quality evidence, variable hormone release, and possible insertion complications.
• Custom creams or troches compounded based on saliva tests: not recommended because dosing and monitoring are unreliable.

Which you should ask for (practical approach)

1. Describe your symptoms, medical history, and priorities (symptom relief, bone protection, fear of risks such as breast cancer or blood clots).
2. Ask for an evidence‑based discussion of options: FDA‑approved estrogen ± appropriate progestogen if you have a uterus, routes (patch, oral, gel), expected benefits and risks, and monitoring. Example FDA‑approved options to discuss:
   • Estradiol patch: Vivelle‑Dot, Climara (stable blood levels; lower clot risk than some oral estrogens)
   • Oral estradiol: Estrace
   • Conjugated estrogens: Premarin (well‑studied historically)
   • Progesterone: Prometrium (micronized progesterone, bioidentical form; differs from medroxyprogesterone/Provera)
3. If you prefer “bioidentical” phrasing, ask whether the prescribed FDA‑approved hormones are bioidentical (many are).
4. If standard therapy doesn’t work or causes side effects, or you have a specific rationale for compounded therapy, ask your clinician to explain the pros/cons and refer you to a reputable compounding pharmacy and skilled prescriber if proceeding.

Where to go / whom to ask

• Primary options: your OB/GYN, a primary care physician experienced in menopause, or an endocrinologist.
• For complex questions or personalized plans, see a menopause specialist: look for a North American Menopause Society (NAMS) Certified Menopause Practitioner (NCMP) or a menopause clinic at an academic center (examples: Mayo Clinic Menopause Clinic, Cleveland Clinic Menopause Center). NAMS has a “find a practitioner” resource.
• If you’re considering compounded BHRT: only proceed with a clinician who understands the limitations and uses reputable compounding pharmacies that follow USP and state board standards. Ask the clinician which compounding pharmacy they use and whether it’s accredited (URAC/PCAB or equivalent).

Monitoring and safety

• Before starting: review medical history (breast cancer, blood clots, liver disease, stroke), baseline mammogram as indicated, and discuss VTE/stroke risks.
• Follow‑up: assess symptom response and side effects at regular intervals; use the lowest effective dose for the shortest needed time for symptom control; bone density testing if bone protection is a goal. Avoid saliva testing for dose adjustment.

Cost and coverage

• FDA‑approved HRT is more likely to be covered by insurance. Compounded BHRT is typically out‑of‑pocket and can cost more long‑term.

Bottom line recommendation

• Ask a menopause‑experienced clinician for an individualized plan and start with an FDA‑approved HRT option that meets your goals and risk profile. Consider compounded BHRT only when a knowledgeable clinician explains why it’s necessary and you accept the uncertainties; if chosen, use an accredited compounding pharmacy and careful follow‑up.

If you want, tell me:

• your age, symptoms, whether you have a uterus, and any medical history (blood clots, breast cancer, stroke, liver disease) and I’ll suggest what to ask a clinician and which specific HRT options to discuss.